Market Overview
The Panitumumab market is predicted to
develop at a compound annual growth rate (CAGR) of xx from
2024 to 2034, when it is projected to reach USD xx Billion, based on an average
growth pattern. The market is estimated to reach a value of USD xx Billion in
2024.
SOURCE: We Market Research
A monoclonal
antibody called panitumumab targets the epidermal growth factor receptor (EGFR)
and is used to treat metastatic colorectal cancer, particularly in patients
with tumors that are KRAS wild-type. When given intravenously, it prevents the
development of cancer cells by obstructing EGFR signaling pathways. Skin rash
and low magnesium levels are common side effects; severe allergic reactions and
lung problems are examples of major ones. Before starting treatment, KRAS
mutation testing is necessary to guarantee efficacy. Panitumumab is sold under
the Vectibix brand and is frequently used with other chemotherapeutic drugs.
The rise in colorectal cancer cases worldwide, technological developments, and the growing inclination towards targeted therapies over conventional chemotherapy because of their greater effectiveness and reduced side effects are the main factors propelling the panitumumab market. The need for treatments based on genetic profiles is increased by the emphasis on customized medicine. The need for panitumumab is further increased by an aging population that is more susceptible to cancer. The market's reach is increased by regulatory approvals for novel indications and combination medicines, and the overall expansion of the market is bolstered by better access to cutting-edge cancer treatments in emerging economies thanks to improved healthcare infrastructure.
Market Scope
Report Attributes |
Description |
Market Size in 2024 |
USD xx Billion |
Market
Forecast in 2034 |
USD xx Billion |
CAGR % 2024-2034 |
xx% |
Base
Year |
2023 |
Historic Data |
2016-2022 |
Forecast
Period |
2024-2034 |
Report USP
|
Production,
Consumption, company share, company heatmap, company production capacity,
growth factors and more |
Segments
Covered |
by
Therapeutic Applications, by Dosage Forms, by Distribution Channels and By
Region |
Regional Scope |
North America,
Europe, APAC, South America and Middle East and Africa |
Country
Scope |
U.S.; Canada;
U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia;
China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico;
Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria |
Panitumumab Industry: Dynamics & Restrains
Market opportunity:
We Market
Research: Panitumumab Dashboard
Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.
Panitumumab Segmentation
Market- By Therapeutic Applications Analysis
By Therapeutic Applications, the Panitumumab Market is Categories into Colorectal Cancer, Others. The Colorectal Cancer segment accounts for the largest share of around 92% in 2024.
The primary driver for Panitumumab in
colorectal cancer treatment is the increasing global incidence of colorectal
cancer, coupled with the drug's effectiveness as a targeted therapy, improving
patient outcomes and survival rates by inhibiting cancer cell growth and
proliferation.
The
following segments are part of an in-depth analysis of the global Panitumumab
market:
Market Segments |
|
by
Dosage Forms |
·
Injectable ·
Others |
by
Distribution Channels |
·
Hospitals ·
Specialty Clinics ·
Pharmacies ·
Others |
Panitumumab Industry: Regional Analysis
North America Market Forecast
North America dominates the Panitumumab Market with the highest revenue generating market with share of more than 48%. The high incidence of colorectal cancer and advanced healthcare infrastructure are primary drivers of Panitumumab market growth. Additionally, substantial healthcare expenditure and the presence of major pharmaceutical companies foster a supportive environment for the adoption of targeted therapies, improving patient outcomes and expanding market potential.
Europe Market Statistics
In Europe, increasing
prevalence of colorectal cancer and robust government support for cancer
research and treatment drive the Panitumumab market. Access to advanced
treatment options and well-established healthcare systems enhance the adoption
of targeted therapies, contributing to market growth and improved patient care.
Asia Pacific Market Forecasts
Asia Pacific is expected to be the fastest-growing regional segment of the Panitumumab market during the forecast period. The Asia-Pacific region shows significant market potential due to rapidly rising cancer incidence and improving healthcare infrastructure significantly boost Panitumumab demand. Expanding healthcare access in emerging economies, coupled with increasing awareness and adoption of advanced cancer treatments, drive market growth, making the region a key focus for pharmaceutical companies.
Key Market Players
1.
Global
Panitumumab Market Introduction and Market Overview
1.1. Objectives of the Study
1.2. Global Panitumumab Market Scope
and Market Estimation
1.2.1. Global Panitumumab Overall
Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2034)
1.2.2. Global Panitumumab Market
Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2034
1.3. Market Segmentation
1.3.1. Therapeutic Applications of
Global Panitumumab Market
1.3.2. Dosage Forms of Global Panitumumab
Market
1.3.3. Distribution Channels of Global Panitumumab
Market
1.3.4. Region of Global Panitumumab
Market
2.
Executive Summary
2.1. Market Dynamics
2.1.1. Drivers
2.1.2. Limitations
2.1.3. Opportunities
2.1.4. Impact Analysis of Drivers and
Restraints
2.2. Pricing Trends Analysis &
Average Selling Prices (ASPs)
2.3. Key Mergers & Acquisitions,
Expansions, JVs, Funding / VCs, etc.
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitutes
2.4.4. Threat of New Entrants
2.4.5. Competitive Rivalry
2.5. Market Investment Opportunity
Analysis (Top Investment Pockets), By Segments & By Region
3.
Global Panitumumab Market Estimates & Historical Trend Analysis (2019 -
2023)
4.
Global Panitumumab Market Estimates & Forecast Trend Analysis, by
Therapeutic Applications
4.1. Global Panitumumab Market
Revenue (US$ Mn) Estimates and Forecasts, by Therapeutic Applications, 2019 to 2034
4.1.1. Colorectal Cancer
4.1.2. Others
5.
Global Panitumumab Market Estimates & Forecast Trend Analysis, by
Dosage Forms
5.1. Global Panitumumab Market
Revenue (US$ Mn) Estimates and Forecasts, by Dosage Forms, 2019 to 2034
5.1.1. Injectable
5.1.2. Others
6.
Global Panitumumab Market Estimates & Forecast Trend Analysis, by
Distribution Channels
6.1. Global Panitumumab Market
Revenue (US$ Mn) Estimates and Forecasts, by Distribution Channels,
2019 to 2034
6.1.1. Hospitals
6.1.2. Specialty Clinics
6.1.3. Pharmacies
6.1.4. Others
7.
Global Panitumumab Market Estimates & Forecast Trend Analysis,
by region
7.1. Global Panitumumab Market
Revenue (US$ Mn) Estimates and Forecasts, by region, 2019 to 2034
7.1.1. North America
7.1.2. Europe
7.1.3. Asia Pacific
7.1.4. Middle East & Africa
7.1.5. South America
8.
North
America Panitumumab Market: Estimates & Forecast Trend Analysis
8.1.
North
America Panitumumab Market Assessments & Key Findings
8.1.1. North America Panitumumab Market
Introduction
8.1.2. North America Panitumumab Market
Size Estimates and Forecast (US$ Million) (2019 – 2034)
8.1.2.1. By Therapeutic
Applications
8.1.2.2. By Dosage Forms
8.1.2.3. By Distribution
Channels
8.1.2.4. By Country
8.1.2.4.1. The U.S.
8.1.2.4.2. Canada
8.1.2.4.3. Mexico
9.
Europe
Panitumumab Market: Estimates & Forecast Trend Analysis
9.1. Europe Panitumumab Market
Assessments & Key Findings
9.1.1. Europe Panitumumab Market
Introduction
9.1.2. Europe Panitumumab Market Size
Estimates and Forecast (US$ Million) (2019 – 2034)
9.1.2.1. By Therapeutic
Applications
9.1.2.2. By Dosage Forms
9.1.2.3. By Distribution
Channels
9.1.2.4.
By
Country
9.1.2.4.1. Germany
9.1.2.4.2. U.K.
9.1.2.4.3. France
9.1.2.4.4. Italy
9.1.2.4.5. Spain
9.1.2.4.6. Russia
9.1.2.4.7. Rest of Europe
10. Asia Pacific Panitumumab
Market: Estimates & Forecast Trend
Analysis
10.1. Asia Pacific Market Assessments
& Key Findings
10.1.1. Asia Pacific Panitumumab Market
Introduction
10.1.2. Asia Pacific Panitumumab Market
Size Estimates and Forecast (US$ Million) (2019 – 2034)
10.1.2.1. By Therapeutic
Applications
10.1.2.2. By Dosage Forms
10.1.2.3. By Distribution
Channels
10.1.2.4. By Country
10.1.2.4.1. China
10.1.2.4.2. Japan
10.1.2.4.3. India
10.1.2.4.4. Australia
10.1.2.4.5. South Korea
10.1.2.4.6. ASEAN
10.1.2.4.7. Rest of Asia Pacific
11. Middle East & Africa Panitumumab
Market: Estimates & Forecast Trend
Analysis
11.1. Middle East & Africa Market
Assessments & Key Findings
11.1.1. Middle
East & Africa Panitumumab
Market Introduction
11.1.2. Middle
East & Africa Panitumumab
Market Size Estimates and Forecast (US$ Million) (2019 – 2034)
11.1.2.1. By Therapeutic
Applications
11.1.2.2. By Dosage Forms
11.1.2.3. By Distribution
Channels
11.1.2.4. By Country
11.1.2.4.1. U.A.E.
11.1.2.4.2. Saudi Arabia
11.1.2.4.3. Egypt
11.1.2.4.4. South Africa
11.1.2.4.5. Rest of Middle East & Africa
12. South America
Panitumumab Market: Estimates &
Forecast Trend Analysis
12.1. South America Market Assessments
& Key Findings
12.1.1. South America Panitumumab Market
Introduction
12.1.2. South America Panitumumab Market
Size Estimates and Forecast (US$ Million) (2019 – 2034)
12.1.2.1. By Therapeutic
Applications
12.1.2.2. By Dosage Forms
12.1.2.3. By Distribution
Channels
12.1.2.4. By Country
12.1.2.4.1. Brazil
12.1.2.4.2. Argentina
12.1.2.4.3. Colombia
12.1.2.4.4. Rest of South America
13. Competition Landscape
13.1. Global Panitumumab Market
Competition Matrix & Benchmarking, by Leading Players / Innovators /
Emerging Players / New Entrants
13.2. Global Panitumumab Market
Competition White Space Analysis, By End-user
13.3. Global Panitumumab Market
Competition Heat Map Analysis, By End-user
13.4. Global Panitumumab Market
Concentration & Company Market Shares (%) Analysis, 2022
14. Company Profiles
14.1.
Amgen.
14.1.1. Company Overview & Key Stats
14.1.2. Financial Performance & KPIs
14.1.3. Product Portfolio
14.1.4. Business Strategy & Recent
Developments
15. Research
Methodology
15.1. External Transportations /
Databases
15.2. Internal Proprietary Database
15.3. Primary Research
15.4. Secondary Research
15.5. Assumptions
15.6. Limitations
15.7. Report FAQs
16. Research
Findings & Conclusion
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
Panitumumab Market size will increase at approximate CAGR of xx% during the forecasted period.
Major companies operating within the Panitumumab Market is Amgen.
North America dominates the market with an active share of 48%.
Only Three Thousand Four Hundred Ninety Nine US dollar
Only Four Thousand Four Hundred Ninety Nine US dollar
Only Five Thousand Four Hundred Ninety Nine US dollar